OncoMatch/Clinical Trials/NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Is NCT04503265 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II for advanced malignant neoplasm.
Treatment: AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced or metastatic malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology · Los Angeles, California
- Johns Hopkins · Baltimore, Maryland
- SCRI Oncology Partners · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04503265 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages